Torbjørn Bjerke comments on the additional data from the Expand clinical trial – September 13, 2023
CEO Torbjørn Bjerke at Börsveckan’s Seminar (Swedish) – September 6, 2023
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
September 12, 2023 RegulatorySynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
September 4, 2023 RegulatorySynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
A MESSAGE FROM OUR CEO
“We are truly at an exciting inflection point for SynAct. I am excited to continue to work with the talented management team we have at SynAct, and we are all eagerly awaiting the upcoming clinical trial results that will build off the strong data demonstrated in the BEGIN study. I want to express our sincere appreciation to our shareholder base for supporting our shared vision of resomelagon and the promise of resolution therapy. Our combined resolve remains strong.”